Company intelligence / Profile preview
Pathways Neuro Pharma
Tomball, Texas, United Statespathwaysnp.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Pathways Neuro Pharma is developing a proprietary non-dopamine agonist gene therapy using an AAV6.2FF vector designed to restore dopaminergic balance and provide long-lasting therapeutic benefit for up to 15 months after a single administration. The company has shifted its primary focus toward rare pediatric neurological diseases, with Juvenile Parkinson’s Disease as its lead indication. No clinical results have been published yet; programs are preclinical or IND-enabling.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Gene therapy (AAV6.2FF vector platform)Combination therapy (gene therapy + pharmaceutical activators)Non-dopamine agonist neuro-regulator modulation
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Pathways Neuro Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pathways Neuro Pharma.